Drug repurposing in oncology—the practice of identifying new antineoplastic indications for established, approved non-cancer medications—has expanded rapidly due to the escalating costs and extended timelines of conventional oncology drug development.
Within this research space, antiparasitic agents (specifically benzimidazoles and ivermectin) have emerged as prominent candidates. While preclinical studies demonstrate multi-targeted biological plausibility, bridging the gap between laboratory research, anecdotal patient reports, and validated clinical practice presents critical scientific and pharmacological challenges.
